Metabolism of Ramelteon in Human Liver Microsomes and Correlation with the Effect of Fluvoxamine on Ramelteon Pharmacokinetics

• Published in: Drug metabolism and disposition Vol. 38; no. 8; pp. 1381 - 1391
• Main Authors: OBACH, R. Scott, RYDER, Tim F
• Format: Journal Article
• Language: English
• Published: Bethesda, MD American Society for Pharmacology and Experimental Therapeutics 01.08.2010
• Subjects: Antidepressive Agents, Second-Generation - metabolism; Biological and medical sciences; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System - analysis; Cytochrome P-450 Enzyme System - metabolism; Drug Interactions; Enzyme Inhibitors - metabolism; Fluvoxamine - metabolism; Humans; Hypnotics and Sedatives - metabolism; Hypnotics and Sedatives - pharmacokinetics; Indenes - metabolism; Indenes - pharmacokinetics; Medical sciences; Microsomes, Liver; Pharmacology. Drug treatments; Human; Agonist; Correlation; Serotonin; Digestive system; Psychotropic; Liver; Hypnotic; Reuptake inhibitor; Microsome; Metabolism; In vitro; Selective serotonin reuptake inhibitor; Ramelteon; Neurotransmitter; Antidepressant agent; Pharmacokinetics; Fluvoxamine; Melatonin receptor
• ISSN: 0090-9556; 1521-009X
• DOI: 10.1124/dmd.110.034009

Ramelteon is a melatonin receptor agonist used as a treatment for insomnia. It is subject to a remarkably large drug-drug interaction (DDI) caused by fluvoxamine coadministration, resulting in a more than 100-fold increase in exposure. The objective of this study was to determine whether the DDI could be estimated using in vitro metabolism data. Ramelteon was shown to undergo hydroxylation in human liver microsomes to eight metabolites via six pathways. The main routes of metabolism included hydroxylation on the ethyl side chain and the benzylic position of the cyclopentyl ring, as assessed through enzyme kinetic measurements. Hydroxylation at the other benzylic position was observed in human intestinal microsomes. Ramelteon metabolism was catalyzed by CYP1A2, CYP2C19, and CYP3A4 as shown through the use of recombinant human cytochrome P450 enzymes and specific inhibitors. In liver, CYP1A2, CYP2C19, and CYP3A4 were estimated to contribute 49, 42, and 8.6%, respectively, whereas in intestine only CYP3A4 contributes. The in vitro data were used to estimate the magnitudes of DDI caused by ketoconazole, fluconazole, and fluvoxamine. The DDIs caused by the former were reliably estimated (1.82-fold estimated versus 1.82-fold actual for ketoconazole; 2.99-fold estimated versus 2.36-fold actual for fluconazole), whereas for fluvoxamine it was underestimated (11.4-fold estimated versus 128-fold actual). This suggests that there may be a limit on the magnitude of DDI that can be estimated from in vitro data. Nevertheless, the example of the fluvoxamine-ramelteon DDI offers a unique example wherein one drug can simultaneously inhibit multiple enzymatic pathways of a second drug.